Top Data Analytics Companies in Boston, MA (147)

Strong Revenue Growth: Inc. 5000 recognitions cite 82% and 72% three-year growth, and investor disclosures note meaningful 2025 revenue scale, indicating sustained multi-year expansion. While precise YoY rates aren’t public, repeated list appearances and disclosed scale point to continued momentum.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in 2025 to support the next phase of growth, expansion, and platform investment. Additional financing and stated plans for strategic acquisitions further reinforce access to growth capital.

Market Expansion: Customer and data footprint expanded to 170M+ patient records across 200+ provider/payer organizations, with more than 2.25M value-based lives added in 2024. Management and media describe ambitions for further expansion via M&A and potential moves beyond the U.S.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Strong Revenue Growth: Sales are reported to have risen from about $39 billion (2023) to more than $43 billion (2025), with 2024–2025 gains attributed to institutional solutions, whole life, and annuities.

Profitability: Operating earnings are characterized as increasing from $2.8 billion in 2024 to nearly $3.9 billion in 2025, a company‑record level.

Investor Backing & Capital Strength: Capital levels are described as strong, with total adjusted capital at $34.4 billion in 2025 and high financial‑strength ratings maintained across major agencies.

Healthy Cash Flow: Cash generation is improving, with free cash flow rising from $149.2M to $163.4M in 2025 and jumping from $36.1M to $90.3M in Q1 2026. Management outlook was raised after Q2 alongside stronger ex‑TAC gross profit and adjusted EBITDA guidance.

Profitability: Profitability is generally trending upward, with 2025 adjusted EBITDA up 7.2% and H1 2026 ex‑TAC gross profit up 11.3%, helped by higher ad spend and better margins with certain digital‑property partners. Although quarterly EBITDA has been uneven, the profit trajectory over multi‑period comparisons remains positive.

Market Expansion: Expansion efforts include the Realize platform and the announced plan to acquire Dianomi, which would broaden the advertiser/publisher footprint beyond organic growth. Scale remains significant at roughly 600M daily active users, supporting the push into adjacent opportunities.

Market Expansion: The company reports a larger operating footprint—supporting around 150 million vehicles and approximately 14 million annual service events—and has expanded via strategic moves such as the Urgently acquisition. New and renewed programs with major automotive and insurance brands further indicate broader market reach.

Strong Market Position & Advantage: Industry recognition such as Frost & Sullivan’s North American Company of the Year honors portrays a commanding position in digitalized roadside assistance. Claims of extensive OEM integrations and deep insurer penetration reinforce an entrenched competitive stance.

Innovation-Driven Growth: Continued investment in software-enabled dispatch platforms, automation, and connected-vehicle tools is emphasized as central to the strategy. Rapid uptake of Crash Response and other digital workflows points to technology-enabled scaling.

Strong Revenue Growth: Revenue has scaled materially, with ARR approaching the $400M mark and leadership targeting expansion toward $1B, alongside earlier signals such as 42% YoY ARR growth and very high renewal/net expansion. Feedback suggests recent indications of ~$300–350M revenue and expanding customer/end‑user coverage reinforce continued momentum.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3B valuation signals strong capital support and confidence in the company’s scaling prospects. Feedback suggests this backing, including associated financing, enables continued product and geographic expansion.

Strong Market Position & Advantage: Repeated recognition as a Leader in Gartner’s DEX Magic Quadrant (2024–2026) and Forrester’s EUEM Wave points to sustained category leadership. Large‑scale enterprise adoption (e.g., 1,500+ customers and 25M+ employees served) further entrenches competitive positioning.

Profitability: Adjusted EBITDA and margins expanded, with Q2 2026 EBITDA up 30% year over year and margin improving to 37%, alongside higher net income. This pattern indicates operating leverage as earnings outpace the top line.

Strong Revenue Growth: Revenue rose 7% in 2025 and accelerated to 11% year over year in Q2 2026, with multiple sequential quarters showing improving trends. The recent trajectory points to faster growth rather than a flat profile.

Healthy Cash Flow: Free cash flow is guided to grow at more than 30% for 2026 and was later raised to the high-40% range, while Q2 2026 generated $57.4M in operating cash. Debt reduction in 1H 2026, including repayment of $205M in convertibles, further supports balance-sheet strength.

Strong Revenue Growth: Recent results indicate FY2026 revenue rose 19% year over year to roughly $2.02B, with Q1 FY2027 revenue up 16% and ARR up 17%. This points to steady double‑digit expansion across both total and recurring revenue.

Customer Loyalty & Retention: Dollar-based net retention is reported around 110–111%, and ARR growth has tracked slightly ahead of revenue growth. These signals suggest existing customers are expanding usage alongside new logo additions.

Healthy Cash Flow: Company materials highlight strong free cash flow alongside growth, including substantial FY2026 free cash flow and robust margins in recent quarters. The business has also returned capital via notable share repurchases.

Strong Revenue Growth: Revenue grew 26% year over year in FY2024. ARR increased 30% in 2023 after crossing the $100M threshold in 2022.

Profitability: Operations remained profitable and cash‑flow positive in FY2024 while the organization expanded to just under 600 employees.

Investor Backing & Capital Strength: A July 2024 majority investment led by Vista Equity Partners (with TCV and KKR) valued the company at about $1.2B. This reflects substantial external capital support for continued expansion.

Strong Revenue Growth: Historical disclosures point to outsized growth (e.g., revenue increasing 5x in 2020 and more than tripling in 2021), and one dataset estimates revenue rose from $21M in 2023 to $31.9M in 2024. Together with an expanding customer base, this indicates continued commercial momentum.

Investor Backing & Capital Strength: Funding totals about $114.5M, including a $71M Series C backed by major firms, and the company attributes a new Boston office in 2023 to continued growth. This capital base and facilities expansion suggest ample resources to scale.

Market Expansion: The company reports serving 1,000+ companies and highlights new offices and international expansion, alongside recent senior hires in revenue and engineering to support scaling. These signals point to ongoing expansion in customers, footprint, and organizational capacity.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Strong Revenue Growth: Feedback suggests revenue expanded meaningfully in 2025 and continued to rise into 2026, albeit at a slower pace. Annual results indicate double-digit growth for 2025, with subsequent quarters still posting year-over-year increases.

Profitability: Feedback suggests margins and earnings improved alongside growth, with operating income and EPS rising year over year. This points to strengthening profitability even as top-line expansion moderates.

Strong Hiring & Retention: Feedback suggests headcount expanded to roughly 62,850, tracking with business demand. The increase in delivery professionals signals continued scaling of execution capacity.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across recent quarters and the latest fiscal year, with momentum reflected in higher quarterly results and a raised full‑year outlook. Near‑term guidance also points to continued expansion through the remainder of the year.

Profitability: Profitability has expanded alongside growth, with operating income and earnings increasing meaningfully in the latest quarter. A subscription‑heavy mix and higher full‑year operating income guidance support margin durability.

Strong Market Position & Advantage: Position in life‑sciences CRM remains dominant, with a very large share of biopharma seats cited by management and many top‑20 pharmas live on next‑gen Vault CRM. Broad adoption across Development and Quality Clouds and continued big‑pharma commitments reinforce competitive advantage.

Strong Revenue Growth: Q4 FY2026 revenue rose 12% year over year to $1.95B, with FY2026 up 5% to $6.93B. Guidance for FY2027 implies roughly 7–8% growth at the midpoint.

Profitability: FY2026 delivered record gross profit and operating income, with GAAP EPS up 12% for the year. Record Q4 and FY results underscore earnings strength exiting FY2026.

Healthy Cash Flow: Free cash flow rose 40% to $1.87B and operating cash flow grew 37% to $2.07B in FY2026. Strong cash generation supported $1.36B of capital returns via buybacks and dividends.